Dublin, Oct. 13, 2016 -- Research and Markets has announced the addition of the "Stem Cell Assay Market by Type (Viability, Differentiation, Cell Identification), Kit (Mesenchymal, IPSCS, Hematopoietic), Product (Flow Cytometer, Detection Kit), Application (Regenerative Medicines, Drug Development), End User - Forecast to 2021" report to their offering.
The global stem cell assay market is expected to reach USD 1,363.3 million by 2021 from USD 536.6 million in 2016, at a CAGR of 20.5% from 2016 to 2021.
Factors such as high prevalence of chronic diseases, increasing investment in research related activities, and technological advancements are driving the growth in the global stem cell assay market. However, stringent regulatory policies and the high cost of stem cell based therapies are the major factors restraining the growth of this market.
The global stem cell assay market has been segmented on the basis of type of assay, kit, detection, instrument, application, end-user, and region. The viability/cytotoxicity segment is expected to account for the largest and fastest-growing segment of the global stem cell assay market in 2016. The increasing focus of the pharmaceutical industries on drug screening has resulted in the increase in demand for stem cell assays.
The major players in the global stem cell assay market include
- Bio Rad
- Cell Bio Labs, Inc.
- Cellular Dynamics International.
- GE Healthcare
- Hemogenix Inc.
- Merck Millipore
- Promega Corporation
- R&D Systems
- Stem Cell Technologies
- Thermo Fisher Scientific Pvt. Ltd
Key Topics Covered:
1 Introduction
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Stem Cell Assay Market, By Technology
7 Stem Cell Assay Market, By Assay
8 Stem Cell Assay Market, By Kits
9 Stem Cell Assay Market, By Product
10 Stem Cell Assays Market, By Application
11 Stem Cell Assays, By End User
12 Regional Analysis
13 Competitive Landscape
14 Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/mj7nn6/stem_cell_assay
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Stem Cells


Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Apple Turns 50: From Garage Startup to AI Crossroads
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Britain Courts Anthropic Amid US Defense Department Dispute
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 



